stockrow
Friday 6 November 2026
Export MGRX’s income statement to Excel — free account
Mangoceuticals, Inc.
MGRX Healthcare Health Information Services
Mangoceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $456,000.00, down 26.0% from fiscal 2024.
- Revenue
- −59.1%
- EPS
- +84.2%
- Free cash flow
- +79.3%
Quarter to June 2026, against a year earlier
0.20
0.01
+5.26%
Follow MGRX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | 1 | 1 | 0 | 0 | +271.4% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | 55.06 | 58.99 | 61.70 | 54.91 | 54.42 | (0.1) pt | ||||||
| EBT | — | — | — | — | — | 0 | (2) | (9) | (9) | (21) | (15) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | (22,450.56) | (1,259.38) | (1,413.74) | (4,527.08) | (4,790.42) | (4,527.1) pt | ||||||
| Net income | — | — | — | — | — | 0 | (2) | (9) | (9) | (21) | (15) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.01 | 0.68 | 0.31 | 0.05 | 0.02 | n/m | |||||
| Earnings | — | — | — | — | — | 0.00 | (2.77) | (8.55) | (4.84) | (2.17) | (1.20) | n/m | ||||||
| Cash flow | — | — | — | — | — | 0.00 | (1.87) | (6.51) | (2.46) | (0.58) | (0.23) | n/m | ||||||
| Capex | — | — | — | — | — | 0.00 | (0.06) | 0.00 | 0.03 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0.00 | (1.93) | (6.52) | (2.42) | (0.58) | (0.23) | n/m | ||||||
| Book value | — | — | — | — | — | 0.00 | 0.85 | 0.72 | 7.05 | 1.51 | 0.73 | n/m | ||||||
| Shares, m | — | — | — | — | — | 17 | 1 | 1 | 2 | 10 | 14 | (12.7%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 6.40 | 7.78 | 16.34 | 10.32 | 7.6 | ||||||
| P/B | — | — | — | — | — | — | 70.38 | 6.04 | 0.34 | 0.49 | 0.26 | 19.3 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 5.39 | 7.68 | 13.08 | 9.59 | 6.5 | ||||||
| EV/FCF | — | — | — | — | — | — | (31.57) | (0.56) | (0.99) | (1.03) | (0.79) | (8.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 0 | (1) | (7) | (5) | (6) | (4) | n/m | |||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | 0 | — | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0 | (1) | (7) | (5) | (6) | (4) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | 0 | 1 | (1) | 1 | (1) | n/m | |||||
| Net debt | — | — | — | — | — | 0 | (1) | (1) | 0 | (1) | 0 | +184.8% | ||||||
| Shareholders’ equity | — | — | — | — | — | 0 | 1 | 1 | 14 | 15 | 13 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (389.53) | (896.98) | (106.03) | (131.23) | (86.27) | (131.2) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | (16,094.45) | (35.88) | (82.19) | (62.76) | (82.2) pt | ||||||
| ROE | — | — | — | — | — | 0.00 | (669.04) | (1,326.67) | (118.29) | (141.66) | (95.09) | (141.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Mangoceuticals, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BFRG Bullfrog AI Holdings Inc. | $9.1M | — (loss-making) | — (loss-making) | +2,054.00% (above 0%: growing) | n/m | −5.67% (below 0%: shrinking) | 49.63% | (658.82%) | Compare |
| HLTHQ Cue Health Inc. | $6.9M | — (loss-making) | — (loss-making) | −87.19% (below 0%: shrinking) | n/m | +50.55% (above 0%: growing) | (90.14%) | (792.13%) | Compare |
| ACON Aclarion, Inc. | $4.5M | — (loss-making) | — (loss-making) | +78.48% (above 0%: growing) | n/m | −74.22% (below 0%: shrinking) | 43.86% | (8,164.70%) | Compare |
| MGRX Mangoceuticals, Inc. | $4.3M | — (loss-making) | — | −59.07% (below 0%: shrinking) | n/m | +79.27% (above 0%: growing) | 64.24% | (1,501.45%) | |
| ZCMD Zhongchao Inc. | $4.3M | — (loss-making) | — | +20.44% (above 0%: growing) | −550.00% (below 0%: shrinking) | +191.85% (above 0%: growing) | 41.67% | 0.00% | Compare |
| HCTI Healthcare Triangle, Inc. | $3.2M | 0.0× | — (loss-making) | +158.38% (above 0%: growing) | n/m | +67.48% (above 0%: growing) | 22.48% | (44.28%) | Compare |
| VSEE VSee Health, Inc. | $2.8M | — (loss-making) | — (loss-making) | −53.93% (below 0%: shrinking) | n/m | −257.62% (below 0%: shrinking) | 13.20% | (172.69%) | Compare |
| WORX SCWorx Corp. | $2.0M | — (loss-making) | — (loss-making) | +3.43% (above 0%: growing) | n/m | +87.99% (above 0%: growing) | 46.80% | (17.14%) | Compare |
| MSPR MSP Recovery, Inc. | $1.5M | — (loss-making) | — | −94.60% (below 0%: shrinking) | n/m | +60.88% (above 0%: growing) | (26.77%) | (62,501.52%) | Compare |
| Median of peers | $3.7M | — | — | +11.94% | — | +55.72% | 32.08% | (415.75%) |
Pay and ownership Proxy statement filed 18 February 2025
Ownership
Directors and executive officers, together
16.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement